Sandoz Completes Strategic Acquisition Of Just-Evotec Biologics EU SAS, Asserting Biosimilars Leadership

• Expands in-house development and manufacturing capabilities for biosimilars, consolidating position as undisputed leader in the sector
• Strengthens position to capture projected >USD 300 billion biosimilars Loss of Exclusivity (LoE) market opportunity over the next decade¹
• Acquisition includes Just-Evotec Biologics EU SAS site in Toulouse and indefinite licence to cutting-edge continuous-manufacturing technology
• Complements ongoing investments in Slovenia, building end-to-end in-house biosimilar development and manufacturing network across Europe
• Fully aligned with existing capital-expenditure commitments; no impact on 2025 full-year guidance

Sandoz, the global leader in affordable medicines, today announced the completion of the acquisition of Just-Evotec Biologics EU SAS (JEB SAS) from Evotec SE. The deal includes the Toulouse development and manufacturing site and an indefinite licence to cutting-edge continuous-manufacturing technology for biosimilars.

This milestone fully aligns with the Sandoz biosimilar strategy, expanding in-house drug substance development and manufacturing capabilities and leveraging continuous-manufacturing technology to boost efficiency and scalability. It further positions Sandoz to capitalize on the projected >USD 300 billion global biosimilars LoE market over the next decade¹.

Richard Saynor, CEO of Sandoz, said: “Biosimilars are the fastest-growing segment of our pipeline as the need of patients and healthcare systems for these critical medicines continues to grow rapidly. This acquisition is a pivotal step toward advancing our ambition to consolidate our position as the undisputed leader in biosimilars. It gives us greater control over our pipeline development and underscores our unwavering commitment to expanding access to high-quality, affordable biologics for millions of patients worldwide.”

The fully automated, high-throughput continuous-manufacturing platform represents a transformative leap in biosimilar production. Sandoz has secured an indefinite license to this cutting-edge technology, which enhances operational efficiency, ensures flexibility and enables cost-effective scalability.

The acquisition complements ongoing investments in Slovenia, reinforcing the Sandoz strategy to build a robust, end-to-end in-house biosimilars network across Europe. By co-locating drug-substance development and manufacturing capabilities and leveraging cutting-edge continuous-manufacturing technology, Sandoz creates operational synergies that support its leadership position in this rapidly growing market. The Slovenian site will focus on large-scale fed-batch drug substance manufacturing, while the Toulouse site will specialize in small-scale continuous manufacturing.

The transaction is in line with existing capital-expenditure commitments and does not impact 2025 guidance. Effective from today, all JEB SAS employees have joined Sandoz.

About Sandoz agreement with JEB
In May 2023, Sandoz and JEB announced a strategic partnership that supported Sandoz portfolio expansion and continued development of its early-stage biosimilar pipeline, by providing access to JEB’s continuous-manufacturing technology platform. The proprietary fully automated and high-throughput technology platform was a strategic addition to Sandoz integrated drug-substance development and manufacturing network.

In July 2024, Sandoz secured long-term commercial supply access to JEB’s biosimilar manufacturing facility in Toulouse, along with additional capacity for drug substance development.

On July 30, 2025, Sandoz signed a non-binding term-sheet to acquire JEB’s biosimilars manufacturing facility in Toulouse, including an indefinite license to continuous-manufacturing technology.

On November 4, 2025, Sandoz announced the signing of an agreement with Evotec SE to acquire all issued and outstanding equity interests of JEB SAS, which includes the Toulouse manufacturing site and an indefinite licence to the continuous-manufacturing technology.